Tumor metastasis: Moving new biological insights into the clinic

Liling Wan; Klaus Pantel; Yibin Kang

doi:10.1038/nm.3391

Tumor metastasis: Moving new biological insights into the clinic

Liling Wan, Klaus Pantel, Yibin Kang

Research output: Contribution to journal › Review article › peer-review

632 Scopus citations

Abstract

As the culprit behind most cancer-related deaths, metastasis is the ultimate challenge in our effort to fight cancer as a life-threatening disease. The explosive growth of metastasis research in the past decade has yielded an unprecedented wealth of information about the tumor-intrinsic and tumor-extrinsic mechanisms that dictate metastatic behaviors, the molecular and cellular basis underlying the distinct courses of metastatic progression in different cancers and what renders metastatic cancer refractory to available therapies. However, integration of such new knowledge into an improved, metastasis-oriented oncological drug development strategy is needed to thwart the development of metastatic disease at every stage of progression.

Original language	English (US)
Pages (from-to)	1450-1464
Number of pages	15
Journal	Nature Medicine
Volume	19
Issue number	11
DOIs	https://doi.org/10.1038/nm.3391
State	Published - Nov 2013
Externally published	Yes

All Science Journal Classification (ASJC) codes

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/nm.3391

Cite this

@article{ea74aecf95ab4eefa3392c3f1584b2f6,

title = "Tumor metastasis: Moving new biological insights into the clinic",

abstract = "As the culprit behind most cancer-related deaths, metastasis is the ultimate challenge in our effort to fight cancer as a life-threatening disease. The explosive growth of metastasis research in the past decade has yielded an unprecedented wealth of information about the tumor-intrinsic and tumor-extrinsic mechanisms that dictate metastatic behaviors, the molecular and cellular basis underlying the distinct courses of metastatic progression in different cancers and what renders metastatic cancer refractory to available therapies. However, integration of such new knowledge into an improved, metastasis-oriented oncological drug development strategy is needed to thwart the development of metastatic disease at every stage of progression.",

author = "Liling Wan and Klaus Pantel and Yibin Kang",

note = "Funding Information: We thank members of our laboratories for helpful discussions and H.A. Smith for critical reading of the manuscript. We also apologize to the many investigators whose important studies could not be cited directly here because of space limitations. The work was supported by a Charlotte Elizabeth Procter Fellowship to L.W., grants from the European Research Council (Advanced Investigator Grant {\textquoteleft}DISSECT{\textquoteright}), the Deutsche Forschungsgemeinschaft and the German Minister of Education and Research (BMBF) to K.P. and grants from the Brewster Foundation, the Champalimaud Foundation, the US Department of Defense, Komen for the Cure and the US National Institutes of Health to Y.K.",

year = "2013",

month = nov,

doi = "10.1038/nm.3391",

language = "English (US)",

volume = "19",

pages = "1450--1464",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Tumor metastasis

T2 - Moving new biological insights into the clinic

AU - Wan, Liling

AU - Pantel, Klaus

AU - Kang, Yibin

N1 - Funding Information: We thank members of our laboratories for helpful discussions and H.A. Smith for critical reading of the manuscript. We also apologize to the many investigators whose important studies could not be cited directly here because of space limitations. The work was supported by a Charlotte Elizabeth Procter Fellowship to L.W., grants from the European Research Council (Advanced Investigator Grant ‘DISSECT’), the Deutsche Forschungsgemeinschaft and the German Minister of Education and Research (BMBF) to K.P. and grants from the Brewster Foundation, the Champalimaud Foundation, the US Department of Defense, Komen for the Cure and the US National Institutes of Health to Y.K.

PY - 2013/11

Y1 - 2013/11

N2 - As the culprit behind most cancer-related deaths, metastasis is the ultimate challenge in our effort to fight cancer as a life-threatening disease. The explosive growth of metastasis research in the past decade has yielded an unprecedented wealth of information about the tumor-intrinsic and tumor-extrinsic mechanisms that dictate metastatic behaviors, the molecular and cellular basis underlying the distinct courses of metastatic progression in different cancers and what renders metastatic cancer refractory to available therapies. However, integration of such new knowledge into an improved, metastasis-oriented oncological drug development strategy is needed to thwart the development of metastatic disease at every stage of progression.

AB - As the culprit behind most cancer-related deaths, metastasis is the ultimate challenge in our effort to fight cancer as a life-threatening disease. The explosive growth of metastasis research in the past decade has yielded an unprecedented wealth of information about the tumor-intrinsic and tumor-extrinsic mechanisms that dictate metastatic behaviors, the molecular and cellular basis underlying the distinct courses of metastatic progression in different cancers and what renders metastatic cancer refractory to available therapies. However, integration of such new knowledge into an improved, metastasis-oriented oncological drug development strategy is needed to thwart the development of metastatic disease at every stage of progression.

UR - http://www.scopus.com/inward/record.url?scp=84887421660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887421660&partnerID=8YFLogxK

U2 - 10.1038/nm.3391

DO - 10.1038/nm.3391

M3 - Review article

C2 - 24202397

AN - SCOPUS:84887421660

SN - 1078-8956

VL - 19

SP - 1450

EP - 1464

JO - Nature Medicine

JF - Nature Medicine

IS - 11

ER -

Tumor metastasis: Moving new biological insights into the clinic

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this